Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879914 | 0.91 | ALDH1A1 (0.31) | ALDH1A1MAPTRHEB | |
| SCHEMBL7879643 | 0.90 | ALDH1A1 (0.34) | ALDH1A1MAPTRHEB | |
| SCHEMBL7879931 | 0.89 | TDP1 (0.33) | ALDH1A1MAPTACHE | |
| SCHEMBL7885078 | 0.88 | RHEB (0.33) | RHEBSLC6A4 | |
| SCHEMBL7881915 | 0.85 | KMT2A (0.38) | ALDH1A1 | |
| SCHEMBL7879832 | 0.84 | KDM4E (0.35) | ALDH1A1MAPTRHEBACHE | |
| SCHEMBL7877544 | 0.84 | SLC6A4 (0.38) | RHEBHTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL7881328 | 0.84 | SLC6A4 (0.37) | ALDH1A1RHEBHTR2ASLC6A4 | |
| SCHEMBL7879828 | 0.83 | RHEB (0.31) | RHEBHTR2ASLC6A4 | |
| SCHEMBL7880844 | 0.82 | ACHE (0.33) | ACHEHTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |